<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42905">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547792</url>
  </required_header>
  <id_info>
    <org_study_id>VXA03-001</org_study_id>
    <nct_id>NCT02547792</nct_id>
  </id_info>
  <brief_title>Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults</brief_title>
  <official_title>Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, single-center, placeb-controlled, double-blind study. The purpose of this
      study is to determine the safety and immunogenicity of an oral vaccine tablet to prevent
      seasonal influenza B tested at two dose levels (low and high dose). The study will enroll 27
      subjects in the low dose cohorts (3 sentinel open label subjects followed by 24 subjects
      (randomized 2:1 to vaccine vs placebo, respectively). Subsequently, 27 subjects will be
      enrolled in the high dose cohort in a similar manner as to the low dose cohort. Safety and
      immunogenicity will be evaluated at Day 28. Long term safety follow-up will be evaluated
      through 1 year post vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Single High Dose of an Oral Influenza B Tablet Vaccine</measure>
    <time_frame>Day 28</time_frame>
    <description>Safety determined by reported solicited (reactogenicity) and unsolicited AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Single high Dose of an Oral Influenza B Tablet Vaccine</measure>
    <time_frame>Day 28</time_frame>
    <description>Efficacy determined by HAI titers at Day 28 post-vaccination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Seasonal Influenza B</condition>
  <arm_group>
    <arm_group_label>Low Dose - Oral Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of low dose oral vaccine tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose - Oral Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of high dose oral vaccine tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo dose (size and number of tablets) to low dose vaccine (part 1) and high dose (part 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza B Oral Vaccine Tablets</intervention_name>
    <description>Enteric coated tablet for oral delivery</description>
    <arm_group_label>Low Dose - Oral Vaccine</arm_group_label>
    <arm_group_label>High Dose - Oral Vaccine</arm_group_label>
    <arm_group_label>Placebo Tablets</arm_group_label>
    <other_name>VXA-BYW.10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health as established by medical history, physical examination, and
             laboratory testing at the time of enrollment.

        Exclusion Criteria:

          -  Positive for B influenza by HAI.

          -  Has had an influenza vaccine in the past 2 years.

          -  Current history of chronic alcohol use and/or illicit and/or recreational drug use.

          -  History of any confirmed or suspected immunodeficient or immunosuppressive condition

          -  Positive serology for HIV, HCV, or HBV

          -  Previous serious reactions to vaccination such as anaphylaxis, respiratory problems,
             hives, or abdominal pain.

          -  History of irritable bowel disease or other inflammatory digestive or
             gastrointestinal conditions that could affect the intended distribution of the
             vaccine targeting the mucosa of the small intestine

          -  Use of proton pump inhibitors(Nexium, Prilosec).

          -  Stool sample with occult blood at baseline exam

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Liebowitz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vaxart, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCST</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 9, 2016</lastchanged_date>
  <firstreceived_date>September 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
